Compensation claims for sub-substandard care of patients with gastroentero-pancreatic neuroendocrine tumors

A nationwide descriptive study of cases between 2005-2016 in norway

Kari F. Desserud, Ida Bukholm, Jon Arne Soreide

Research output: Contribution to journalArticle

Abstract

Background: Management of patients with neuroendocrine tumors of the gastrointestinal tract or pancreas (GEP-NENs) poses diagnostic and therapeutic challenges. This study described the medico-legal claims reported to a national governmental system that oversees compensation to patients with GEP-NENs Materials and Methods: An electronic search of the Norwegian System of Compensation to Patients database was performed to identify claims evaluated between 2005-2016. The clinical information and the medico-legal evaluation were reviewed. Results: We identified seven patients, five women and two men, with a median age of 57 (range=47-73) years. Delayed diagnosis (median diagnostic delay of 18 (range=6-48) months) was the main cause for claims in six out of the seven patients). Four patients received financial compensation based on the claim judgement. Conclusion: This review of claims that were evaluated by the Norwegian System of Compensation to Patients showed that a timely diagnosis of GEP-NENs remains a clinical challenge.

Original languageEnglish (US)
Pages (from-to)5667-5671
Number of pages5
JournalAnticancer Research
Volume37
Issue number10
DOIs
StatePublished - Oct 1 2017

Fingerprint

Neuroendocrine Tumors
Norway
Patient Care
Insurance Claim Review
Delayed Diagnosis
Gastrointestinal Tract
Pancreas
Databases

Keywords

  • Claim
  • Diagnostic delay
  • Gastroentero-pancreatic neuroendocrine neoplasms
  • Litigation
  • Medico-legal
  • Neuroendocrine tumors

ASJC Scopus subject areas

  • Oncology
  • Cancer Research

Cite this

@article{aeb02985b3304a6bab330144af6855c0,
title = "Compensation claims for sub-substandard care of patients with gastroentero-pancreatic neuroendocrine tumors: A nationwide descriptive study of cases between 2005-2016 in norway",
abstract = "Background: Management of patients with neuroendocrine tumors of the gastrointestinal tract or pancreas (GEP-NENs) poses diagnostic and therapeutic challenges. This study described the medico-legal claims reported to a national governmental system that oversees compensation to patients with GEP-NENs Materials and Methods: An electronic search of the Norwegian System of Compensation to Patients database was performed to identify claims evaluated between 2005-2016. The clinical information and the medico-legal evaluation were reviewed. Results: We identified seven patients, five women and two men, with a median age of 57 (range=47-73) years. Delayed diagnosis (median diagnostic delay of 18 (range=6-48) months) was the main cause for claims in six out of the seven patients). Four patients received financial compensation based on the claim judgement. Conclusion: This review of claims that were evaluated by the Norwegian System of Compensation to Patients showed that a timely diagnosis of GEP-NENs remains a clinical challenge.",
keywords = "Claim, Diagnostic delay, Gastroentero-pancreatic neuroendocrine neoplasms, Litigation, Medico-legal, Neuroendocrine tumors",
author = "Desserud, {Kari F.} and Ida Bukholm and Soreide, {Jon Arne}",
year = "2017",
month = "10",
day = "1",
doi = "10.21873/anticanres.12002",
language = "English (US)",
volume = "37",
pages = "5667--5671",
journal = "Anticancer Research",
issn = "0250-7005",
publisher = "International Institute of Anticancer Research",
number = "10",

}

TY - JOUR

T1 - Compensation claims for sub-substandard care of patients with gastroentero-pancreatic neuroendocrine tumors

T2 - A nationwide descriptive study of cases between 2005-2016 in norway

AU - Desserud, Kari F.

AU - Bukholm, Ida

AU - Soreide, Jon Arne

PY - 2017/10/1

Y1 - 2017/10/1

N2 - Background: Management of patients with neuroendocrine tumors of the gastrointestinal tract or pancreas (GEP-NENs) poses diagnostic and therapeutic challenges. This study described the medico-legal claims reported to a national governmental system that oversees compensation to patients with GEP-NENs Materials and Methods: An electronic search of the Norwegian System of Compensation to Patients database was performed to identify claims evaluated between 2005-2016. The clinical information and the medico-legal evaluation were reviewed. Results: We identified seven patients, five women and two men, with a median age of 57 (range=47-73) years. Delayed diagnosis (median diagnostic delay of 18 (range=6-48) months) was the main cause for claims in six out of the seven patients). Four patients received financial compensation based on the claim judgement. Conclusion: This review of claims that were evaluated by the Norwegian System of Compensation to Patients showed that a timely diagnosis of GEP-NENs remains a clinical challenge.

AB - Background: Management of patients with neuroendocrine tumors of the gastrointestinal tract or pancreas (GEP-NENs) poses diagnostic and therapeutic challenges. This study described the medico-legal claims reported to a national governmental system that oversees compensation to patients with GEP-NENs Materials and Methods: An electronic search of the Norwegian System of Compensation to Patients database was performed to identify claims evaluated between 2005-2016. The clinical information and the medico-legal evaluation were reviewed. Results: We identified seven patients, five women and two men, with a median age of 57 (range=47-73) years. Delayed diagnosis (median diagnostic delay of 18 (range=6-48) months) was the main cause for claims in six out of the seven patients). Four patients received financial compensation based on the claim judgement. Conclusion: This review of claims that were evaluated by the Norwegian System of Compensation to Patients showed that a timely diagnosis of GEP-NENs remains a clinical challenge.

KW - Claim

KW - Diagnostic delay

KW - Gastroentero-pancreatic neuroendocrine neoplasms

KW - Litigation

KW - Medico-legal

KW - Neuroendocrine tumors

UR - http://www.scopus.com/inward/record.url?scp=85031115889&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85031115889&partnerID=8YFLogxK

U2 - 10.21873/anticanres.12002

DO - 10.21873/anticanres.12002

M3 - Article

VL - 37

SP - 5667

EP - 5671

JO - Anticancer Research

JF - Anticancer Research

SN - 0250-7005

IS - 10

ER -